Here's Why Mallinckrodt Fell Over 17% Today

What happened

Shares of Mallinckrodt (NYSE: MNK) dropped as much as 17.3% today on multiple news items. The company reported that an appeals court has ruled that patents covering INOmax, the company's inhaled nitric oxide product, were not infringed upon by competing drug Noxivent from Praxair. That wasn't all.

On Monday, news broke that a judge in Oklahoma had ordered Johnson & Johnson to pay $572 million for its role in the opioid crisis in the state. That wasn't quite the $17 billion that state prosecutors had sought, but it was more than the $270 million paid by Purdue Pharma and the $85 million paid by Teva Pharmaceuticals earlier this year.

Mallinckrodt is also listed in lawsuits stemming from the opioid crisis in states across the country. Investors are transitioning from optimism to pessimism about how the company will fare in court. As of 3:38 p.m. EDT, the stock had settled to a 14.7% loss.

Multiple declining lines and arrows on a chalkboard.

Image source: Getty Images.

So what

Investors are right to be a least a little worried about encroaching competition for INOmax, which generated $291 million in net sales, or 18% of Mallinckrodt's total revenue, in the first half of 2019. It doesn't help that the company's lead drug brand, Acthar Gel, has seen sales decline 9% in the last year. 

Falling drug sales is an unwelcome trend in any environment, but doubly so given the uncertainty surrounding the pending opioid litigation. That uncertainty forced Mallinckrodt to suspend plans to spin off its specialty pharmaceutical division, which is responsible for 76% of revenue in the first half of 2019, earlier this month.

Now what

Few things can sabotage a business as quickly as uncertainty -- and Mallinckrodt has multiple sources of it. Case in point: Its shares have fallen 90% in the last year. Until more is known about the specific financial responsibility the company will bear in the opioid crisis, investors can expect plenty of volatility.

10 stocks we like better than Mallinckrodt
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Mallinckrodt wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More